Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic Association of Curative and Adverse Reactions to Tyrosine Kinase Inhibitors in Chinese advanced Non-Small Cell Lung Cancer patients.

Scientific reports - 18 Mar 2016

Ruan Yunfeng, Jiang Jie, Guo Liang, Li Yan, Huang Hailiang, Shen Lu, Luan Mengqi, Li Mo, Du Huihui, Ma Cheng, He Lin, Zhang Xiaoqing, Qin Shengying

Abstract excerpt

Epidermal growth factor receptor (EGFR) Tyrosine kinase inhibitor (TKI) is an effective targeted therapy for advanced non-small cell lung cancer (NSCLC) but also causes adverse drug reactions (ADRs) e.g., skin rash and diarrhea. SNPs in the EGFR signal pathway, drug metabolism/ transport pathways and miRNA might contribute to the interpersonal difference in ADRs but biomarkers for therapeutic responses and ADRs...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ATP Binding Cassette Transporter, Subfamily B
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Crown Ethers

Share to Erlotinib Hydrochloride

Share to Gefitinib

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-akt

Share to Quinazolines

Source

Open in PubMed Open full text

Identifiers

PMID: 26988277
DOI: 10.1038/srep23368
PMCID: PMC4796893

Genes

EGFR
ABCB1
AKT1
MET

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic Association of Curative and Adverse Reactions to Tyrosine Kinase Inhibitors in Chinese advanced Non-Small Cell Lung Cancer patients.PMID 26988277Read ↗

STAT3 and STAT6 polymorphisms predict the severity of adverse reactions in Chinese NSCLC patients receiving EGFR-TKIs therapy.Semantic proximity Read ↗

Association of JAK/STAT pathway gene polymorphisms with EGFR-TKIs adverse drug reactions in patients with advanced NSCLCSemantic proximity Read ↗

Polymorphisms of NF-κB pathway genes influence adverse drug reactions of gefitinib in NSCLC patients.Semantic proximity Read ↗

Influence of SNVs on adverse reactions and survival in gefitinib-treated lung cancer patients from a preliminary study.Semantic proximity Read ↗

Population Pharmacokinetics and Adverse Events of Erlotinib in Japanese Patients with Non-small-cell Lung Cancer: Impact of Genetic Polymorphisms in Metabolizing Enzymes and Transporters.Semantic proximity Read ↗

Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a pharmacogenomic study of metabolic enzymes and transporters.Semantic proximity Read ↗

Influence of genetic polymorphisms on gefitinib pharmacokinetics and adverse drug reactions in non-small cell lung cancer patients.Semantic proximity Read ↗

The role of pharmacoethnicity in the development of cytotoxic and molecular targeted drugs in oncology.Semantic proximity Read ↗

Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis.Semantic proximity Read ↗

Pharmacogenetics for severe adverse drug reactions induced by molecular-targeted therapy.Semantic proximity Read ↗

Polymorphisms in EGFR and VEGF contribute to non-small-cell lung cancer survival in a Chinese population.Semantic proximity Read ↗

Association of genetic polymorphisms of CYP3A4 and CYP2D6 with gefitinib-induced toxicities.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.